Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease

Biomarkers

Volumn 15, Issue 2, 2010, Pages 97-103

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

COPD biomarkers systemic inflammation inhaled therapies

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; BUDESONIDE; C REACTIVE PROTEIN; CLARA CELL PROTEIN; CORTICOSTEROID; FIBRINOGEN; FLUTICASONE PROPIONATE; FORMOTEROL; INTERLEUKIN 6; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; PREDNISONE; SALMETEROL; SECRETORY PROTEIN; SURFACTANT PROTEIN D; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; QUALITY OF LIFE; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; FIBRINOGEN; HUMANS; INFLAMMATION; INTERLEUKIN-6; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RECEPTORS, ADRENERGIC, BETA-2; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UTEROGLOBIN;

EID: 77249129917     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903311902     Document Type: Review

References (61)

1. Antoniu Sa, Mihaescu T, Donner CF. (2007). Inhaled therapy for stable chronic obstructive pulmonary disease. Expert Opin Pharmacother 8:777-85.
2. Atochina En, Beers MF, Hawgood S et al. (2004). Surfactant protein-D, a mediator of innate lung immunity, alters the products of nitric oxide metabolism. Am J Respir Cell Mol Biol 30:271-9.
3. Barnes Nc, Qiu Y-S, Pavord ID et al. (2006). Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173:736-43.
4. Bernard A, Marchandise Fx, Depelchin S, Lauwerys R, Sibille Y (1992). Clara cell protein in serum and bronchoalveolar lavage. Eur Respir J 5:1231-8.
5. Bolton PB, Lefevre P, Mcdonald DM. (1997). Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 155:1428-35.
6. Bowden JJ, Sulakvelidze I, Mcdonald DM. (1994). Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol. J Appl Physiol 77:397-405.
7. Braido F, Riccio AM, Guerra L et al.. (2007). Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respir Med 101:2119-24.
8. Burge PS, Calverley PM, Jones PW et al. (2000). Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320:1297-303.
9. Calverley P, Pauwels R, Vestbo J et al. (2003a). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361:449-56.
10. Calverley PM, Boonsawat W, Cseke Z et al. (2003b). Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22:912-19.
11. Calverley P, Ferguson GT, Anderson JA, Celli B, Jenkins C, Jones PW, Yates VC, Pride N. (2006). The Torch (Towards A Revolution In COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. Eur Resp J 28:E-poster E311.
12. Casaburi R, Mahler DA, Jones PW et al. (2002). A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19:217-24.
13. Cazzola M, Matera MG, Santangelo G et al. (1995). Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 89:357-62.
14. Chaouat A, Savale L, Chouaid C et al. (2009). Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 136;678-87.
15. Cheng G, Ueda T, Numao T et al. (2000). Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J 16:831-5.
16. Dahl M, Vestbo J, Lange P et al. (2007). C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:250-5.
17. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. (2001). Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:1008-11.
18. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. (1996). Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 153:633-7.
19. De Torres JP, Pinto-Plata V, Casanova C et al. (2008). C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133:1336-43.
20. Di Francia M, Barbier D, Mege JL, Orehek J. (1994). Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150:1453-5.
21. Dougherty JA, Didur BL, Aboussouan LS. (2003). Long-acting inhaled beta 2-agonists for stable COPD. Ann Pharmacother 37:1247-55.
22. Gan Wq, Man Sf, Senthilselvan A, Sin DD. (2004). Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59:574-80.
23. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. (2007). The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 16:236-40.
24. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. (2002). Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 57:799-803.
25. GOLD Workshop Report (2008). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (Updated 2008). Available at: http://www.goldcopd.com [last accessed 21 September 2009].
26. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. (2002). The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 165:1592-6.
27. He JQ, Foreman MG, Shumansky K et al. (2009). Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 64:698-704.
28. Heinrich PC, Behrmann I, Haan S et al. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20.
29. Hermans C, Dong P, Robin M et al. (2003). Determinants of serum levels of surfactant proteins A and B and Clara cell protein CC16. Biomarkers 8:461-71.
30. Higashimoto Y, Iwata T, Okada M et al. (2009). Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 103:1231-8.
31. Honda Y, Kuroki Y, Matsuura E et al. (1995). Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152:1860-6.
32. Husereau D, Shukla V, Boucher M, Mensinkai S, Dales R. (2004). Long acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. BMC Pulm Med 4:7.
33. Jiang R, Burke GL, Enright PL et al. (2008). Inflammatory markers and longitudinal lung function decline in the elderly. Am J Epidemiol 168:602-10.
34. Johnson M, Rennard S. (2001). Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 120:258-70.
35. Jones PW, Bosh TK. (1997). Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 155:1283-9.
36. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. (1997). Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542-8.
37. Keatings VM, Collins PD, Scott DM, Barnes PJ. (1996). Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153:530-4.
38. Kim V, Rogers TJ, Criner GJ. (2008). New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 5:478-85.
39. Lee TM, Lin MS, Chang NC. (2008). Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 101:530-5.
40. Lomas DA, Silverman EK, Edwards LD et al. (2009). Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 34:95-102.
41. Lomas DA, Silverman EK, Edwards LD et al. (2008). Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 63:1058-63.
42. Mukhopadhyay S, Hoidal JR, Mukherjee TK. (2006). Role of TNFalpha in pulmonary pathophysiology. Respir Res 7:125.
43. O'Donnell RA, Peebles C, Ward JA et al. (2004). Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 59:837-42.
44. Pauwels RA, Lofdahl CG, Laitinen LA et al. (1999). Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340:1948-53.
45. Pepys MB, Hirschfield GM. (2003). C-reactive protein: a critical update. J Clin Invest 111:1805-12.
46. Pepys MB, Baltz ML. (1983). Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141-212.
47. Pieper MP, Chaudhary NI, Park JE. (2007). Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci 80:2270-3.
48. Pilette C, Godding V, Kiss R et al. (2001). Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:185-94.
49. Pinto-Plata VM, Mullerova H, Toso JF et al. (2006). C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61:23-8.
50. Powrie DJ, Wilkinson TM, Donaldson GC et al. (2007). Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 30:472-8.
51. Profita M, Bonanno A, Siena L et al. (2008). Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J Pharmacol 582:145-53.
52. Sin DD, Man SF, Marciniuk DD et al. (2008). The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177:1207-14.
53. Sin DD, Leung R, Gan WQ, Man SP. (2007). Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 7:13.
54. Sin DD, Lacy P, York E, Man SF. (2004). Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170:760-5.
55. Sin DD, Logan AG, Fitzgerald FS, Liu PP, Bradley TD. (2000). Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 102:61-6.
56. Szafranski W, Cukier A, Ramirez A et al. (2003). Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21:74-81.
57. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. (2003). Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 58:937-41.
58. Takabatake N, Nakamura H, Abe S et al. (2000). The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:1179-84.
59. Tashkin DP, Celli B, Senn S et al. (2008). A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-54.
60. Vestbo J, Sorensen T, Lange P et al. (1999). Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353:1819-23.
61. Vincken W, Van Noord JA, Greefhorst AP et al. (2002). Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 19:209-16.